【LBA5: Event-free survival in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).】【LBA4002: Trastuzumab de
讲者：彭智
单位：北京大学肿瘤医院
【LBA1：Randomized trial of standard chemotherapy alone or combined withatezolizumab as adjuvant therapy for patients with stage lll deficient DNAmismatch repair (dMMR) colon cancer (Aliance A021502; ATOMIC)】【LBA3500：First-line encorafenib + cetuximab + mFO
讲者：王峰
单位：中山大学肿瘤防治中心
讲者：周爱萍
单位：中国医学科学院肿瘤医院
【6011: REMATCH2201: A phase II study on reducing surgical margins in HPV-negative advanced HNSCC with neoadjuvant PD-1 inhibitor and AP chemotherapy.】【6012：Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced h
讲者：杨坤禹
单位：华中科技大学同济医学院附属协和医院
讲者：郭晔
单位：同济大学附属东方医院
LBA6003：PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized contro
讲者：徐骋
6014：A randomized, open-label, multicenter, blank-controlled, phase IV clinical trial of Biyan Qingdu Granula in attenuating acute nose and oral damage in patients undergoing radiotherapy for nasopharyngeal carcinoma.
讲者：刘志刚
单位：南方医科大学第十附属医院（东莞市人民医院）
LBA6005：Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label study.
讲者：王晓慧
【7000：Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial.】【7014：Fixed duration subcutaneous (SC) mosunetuzumab (Mosun) in patients with previously untreated high-tumor burden follicular lymphoma (FL)
讲者：赵东陆
单位：哈尔滨血液病肿瘤研究所
